KRAS and neoplasm: In vivo, KRAS siRNAGAT containing suppression of endogenous RNA (pSUPER) vector plus gemcitabine resulted in a prolonged survival rate of 64 days and dramatically reduced the mean tumor volume compared with single agents (52 days for gemcitabine, 45 days for KRAS siRNAGAT containing pSUPER vector) (Rejiba et al., 2007).